Literature DB >> 28693262

AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway.

Hailiang Xu1, Yunyun Feng2, Zhankui Jia3, Jinjian Yang3, Xueren Lu1, Jun Li1, Mingliang Xia1, Chunru Wu4, Yonggang Zhang5, Jianhua Chen6.   

Abstract

Axis inhibition protein 1 (AXIN1) is characterized as a tumor suppressor in numerous types of cancer. However, the functional role of AXIN1 in the testicular germ cell tumors (TGCTs) remains unclear. The human embryonal carcinoma-derived cell line NTera2 was transfected with a recombinant AXIN1 expression vector (pcDNA3.1-AXIN1) and/or a small interfering RNA (siRNA) directed against AXIN1 (siAXIN). Following transfection, the mRNA and protein levels of AXIN1 were determined via reverse transcription-quantitative polymerase chain reaction analysis and western blotting, respectively. In addition, cell viability, apoptosis and the expression of apoptosis-associated proteins [apoptosis regulator Bax (Bax) and B-cell lymphoma (Bcl)-2] and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway proteins [phosphorylated (p)-mTOR, mTOR, p-AKT, AKT, P-70S ribosomal protein S6 (S6) and S6] were assessed. AXIN1 mRNA and protein levels were increased following transfection with pcDNA3.1-AXIN1 and decreased following transfection with siAXIN1 compared with their respective control groups. After overexpression of AXIN1, NTera2 cell viability and expression of Bcl-2, p-mTOR p-AKT and p-S6 protein was decreased, while apoptosis and Bax protein levels were increased, compared with the control group. However, there was no significant difference in AXIN1 mRNA expression, apoptosis or Bax/Bcl-2 protein expression when NTera2 cells were simultaneously transfected with pcDNA3.1-AXIN1+siAXIN1. In conclusion, the results of the present study indicate that overexpression of AXIN1 protects against TGCTs via inhibiting the PI3K/AKT/mTOR signaling pathway, suggesting that AXIN1 may be a potential target for gene therapy in TGCTs.

Entities:  

Keywords:  PI3K/AKT/mTOR signaling pathway; axis inhibition protein 1; testicular germ cell tumors

Year:  2017        PMID: 28693262      PMCID: PMC5494680          DOI: 10.3892/ol.2017.6214

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  [AXIN1-related CSRNP1 mRNA expression and its transcriptional regulation in TGF-β1-induced tumor cells].

Authors:  Fan Deng; Songyu Li; Wanfu Xu; Zhipeng Zou; Zhiyong Ke; Fangyin Zeng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2013-08

Review 3.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

4.  Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling.

Authors:  Y Zhang; S Y Neo; X Wang; J Han; S C Lin
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

Review 5.  The links between axin and carcinogenesis.

Authors:  S Salahshor; J R Woodgett
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

6.  Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

Authors:  Travis L Biechele; Rima M Kulikauskas; Rachel A Toroni; Olivia M Lucero; Reyna D Swift; Richard G James; Nick C Robin; David W Dawson; Randall T Moon; Andy J Chien
Journal:  Sci Signal       Date:  2012-01-10       Impact factor: 8.192

7.  Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas.

Authors:  R P Dahmen; A Koch; D Denkhaus; J C Tonn; N Sörensen; F Berthold; J Behrens; W Birchmeier; O D Wiestler; T Pietsch
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 8.  Testicular cancer: a prototypic tumor of young adults.

Authors:  Brandon Hayes-Lattin; Craig R Nichols
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

9.  The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc.

Authors:  Hugh K Arnold; Xiaoli Zhang; Colin J Daniel; Deanne Tibbitts; Julie Escamilla-Powers; Amy Farrell; Sara Tokarz; Charlie Morgan; Rosalie C Sears
Journal:  EMBO J       Date:  2009-01-08       Impact factor: 11.598

10.  Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.

Authors:  Andrea Cavazzoni; Mara A Bonelli; Claudia Fumarola; Silvia La Monica; Kinda Airoud; Ramona Bertoni; Roberta R Alfieri; Maricla Galetti; Stefano Tramonti; Elena Galvani; Adrian L Harris; Lesley-Ann Martin; Daniele Andreis; Alberto Bottini; Daniele Generali; Pier Giorgio Petronini
Journal:  Cancer Lett       Date:  2012-04-03       Impact factor: 8.679

View more
  3 in total

1.  A Random Forest-Based Genome-Wide Scan Reveals Fertility-Related Candidate Genes and Potential Inter-Chromosomal Epistatic Regions Associated With Age at First Calving in Nellore Cattle.

Authors:  Anderson Antonio Carvalho Alves; Rebeka Magalhães da Costa; Larissa Fernanda Simielli Fonseca; Roberto Carvalheiro; Ricardo Vieira Ventura; Guilherme Jordão de Magalhães Rosa; Lucia Galvão Albuquerque
Journal:  Front Genet       Date:  2022-05-18       Impact factor: 4.772

2.  Localization and in silico-based functional analysis of miR-202 in bull testis.

Authors:  Bushra T Mohammed; F Xavier Donadeu
Journal:  Reprod Domest Anim       Date:  2022-05-26       Impact factor: 1.858

Review 3.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.